Bupivacaine-d9
(Synonyms: RAC-布比卡因-D9) 目录号 : GC46959An internal standard for the quantification of bupivacaine
Cas No.:474668-57-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Bupivacaine-d9 is intended for use as an internal standard for the quantification of bupivacaine by GC- or LC-MS. Bupivacaine is a sodium channel blocker and local anesthetic.1,2 It inhibits sodium currents in rat dorsal horn neurons in a concentration-dependent manner and inhibits synaptic transmission in rat sympathetic ganglia, increasing the firing threshold when used at a concentration of 200 nM.3,4 Bupivacaine (10 µM) blocks cardiac sodium channels in a use-dependent manner and inhibits respiration in cardiac cell mitochondria when palmitoyl-carnitine or acetyl-carnitine are used as substrates (IC50s = 0.78 and 0.37 mM, respectively).1,5 It also reduces thermal hyperplasia in a rat model of sciatic ligation injury when 0.6 ml of a 0.5% solution is administered into the perinerve space, and the duration of this effect is extended by co-administration of the NMDA receptor antagonist MK-801 .2 Formulations containing bupivacaine have been used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals.
1.Arlock, P.Actions of three local anaesthetics: lidocaine, bupivacaine and ropivacaine on guinea pig papillary muscle sodium channels (Vmax)Pharmacol. Toxicol.63(2)96-104(1988) 2.Mao, J., Price, D.D., Mayer, D.J., et al.Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathyBrain Res.576(2)254-262(1992) 3.Olschewski, A., Hempelmann, G., Vogel, W., et al.Blockade of Na+ and K+ currents by local anesthetics in the dorsal horn neurons of the spinal cordAnesthesiology88(1)172-179(1998) 4.Tabatabai, M., and Booth, A.M.Mechanism of action of local anesthetics on synaptic transmission in the ratAnesth. Analg.71(2)149-157(1990) 5.Weinberg, G.L., Palmer, J.W., VadeBoncouer, T.R., et al.Bupivacaine inhibits acylcarnitine exchange in cardiac mitochondriaAnesthesiology92(2)523-528(2000)
Cas No. | 474668-57-0 | SDF | |
别名 | RAC-布比卡因-D9 | ||
Canonical SMILES | CC1=CC=CC(C)=C1NC(C2N(C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])CCCC2)=O | ||
分子式 | C18H19D9N2O | 分子量 | 297.5 |
溶解度 | DMF: 30 mg/ml,DMSO: 25 mg/ml,Ethanol: 30 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.3613 mL | 16.8067 mL | 33.6134 mL |
5 mM | 0.6723 mL | 3.3613 mL | 6.7227 mL |
10 mM | 0.3361 mL | 1.6807 mL | 3.3613 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。